Investor Centre

Our broad clinical and preclinical pipeline in oncology and behavioural brain disorders focuses on indications including glioblastoma, neurodevelopmental disorders, addiction, anxiety, fatigue and narcolepsy.
Stat background
0.23 GBX Volume: 5,779,847 Market Capitalisation (m) £4.94

TheraCryf plc Investor Presentation

03 - June - 2025
TheraCryf presents annual results to March 2025

Singer Capital Markets

13 - June - 2025
TheraCryf announces Singer Capital Markets as Nominated Advisor and joint broker

Ox-1 – A deep dive into TheraCryf’s addiction programme

11 - June - 2025
Dr Helen Kuhlman and Dr Fraser Murray introduce Orexin-1 and discuss the development programme over the next 12-18 months.

Major Shareholders

Current ShareholderNumber of sharesPercentage holding
Northern Standard Limited422,727,27219.67%
First Equity Limited179,000,0008.33%
T and I Limited160,000,0007.45%
Spreadex Limited93,050,0014.33%
Oberon Investments Limited 80,475,0003.74%
A Leach80,000,0003.72%
S Gibeon71,400,0003.32%
J. R. Kight56,100,000 2.61%
Rathbones Investment Management Ltd24,835,7041.16%
Octopus Investments21,875,0001.02%
Vulpes Investment Management Pte Ltd20,554,1910.96%
Seneca Partners Limited16,301,4560.76%
The number of ordinary shares in issue is 2,148,963,739 all of which are in public hands. The Company does not hold any shares in Treasury.
Last updated 13 June 2025